BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. 2007;26:3661-3678. [PMID: 17530020 DOI: 10.1038/sj.onc.1210377] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene 2012;31:1217-27. [PMID: 21785464 DOI: 10.1038/onc.2011.314] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
2 Abdelwahab S, Azmy A, Abdel-aziz H, Salim H, Mahmoud A. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J Cancer Res Clin Oncol 2012;138:1487-92. [DOI: 10.1007/s00432-012-1229-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
3 Ikeda Y, Kojima T, Kuroda S, Endo Y, Sakai R, Hioki M, Kishimoto H, Uno F, Kagawa S, Watanabe Y, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T. A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system. J Immunol 2009;182:1763-9. [PMID: 19155526 DOI: 10.4049/jimmunol.182.3.1763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. Dis Colon Rectum 2009;52:1144-51; discussion 1152-3. [PMID: 19581859 DOI: 10.1007/DCR.0b013e31819edbf9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lin C, Yang S, Peng C, Shieh M. Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy. ACS Appl Mater Interfaces 2018;10:6096-106. [DOI: 10.1021/acsami.7b13431] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
6 Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, Pan H, Wang X, Chen L, Zhao Q. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep. 2017;38:1383-1392. [PMID: 28731151 DOI: 10.3892/or.2017.5828] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
7 Zhang Y, Qin L, Ma X, Wang Y, Wu Y, Jiang J. Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer. Dis Markers 2020;2020:8831466. [PMID: 33005257 DOI: 10.1155/2020/8831466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Shui X, Huang J, Li YH, Xie PL, Li GC. Construction and selection of human Fab antibody phage display library of liver cancer. Hybridoma (Larchmt) 2009;28:341-7. [PMID: 19857115 DOI: 10.1089/hyb.2009.0028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 194] [Article Influence: 0.8] [Reference Citation Analysis]
9 Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN. Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. Invest New Drugs 2012;30:395-402. [PMID: 20820907 DOI: 10.1007/s10637-010-9533-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
10 Miki Y, Maeda K, Hosono M, Nagahara H, Hirakawa K, Shimatani Y, Tsutsumi S, Miki Y. Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. J Radiat Res 2014;55:1171-7. [PMID: 25129557 DOI: 10.1093/jrr/rru063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
11 Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, Tatematsu M. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 2008;99:1471-1478. [PMID: 18422755 DOI: 10.1111/j.1349-7006.2008.00821.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
12 Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Annals of Oncology 2008;19:1141-5. [DOI: 10.1093/annonc/mdn020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
13 Toda M. Glioma antigen. Adv Exp Med Biol 2012;746:77-84. [PMID: 22639160 DOI: 10.1007/978-1-4614-3146-6_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
14 Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637-646. [PMID: 23506979 DOI: 10.1016/j.molonc.2013.02.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
15 Burgdorf SK, Nielsen HJ, Rosenberg J. Immunotherapy in colorectal cancer. Scandinavian Journal of Gastroenterology 2009;44:261-8. [DOI: 10.1080/00365520802400909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Berardi R, Onofri A, Pistelli M, Maccaroni E, Scartozzi M, Pierantoni C, Cascinu S. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010;5:61-76. [PMID: 21042543 DOI: 10.2147/ce.s7035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
17 Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncologica 2010;49:833-6. [DOI: 10.3109/0284186x.2010.482104] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
18 Li T, Jin X, Dong J, Deng H. Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. J Gene Med 2020;22:e3241. [PMID: 32558022 DOI: 10.1002/jgm.3241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Chen DJ, Tan Z, Chen F, Du T. Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate. World J Gastroenterol 2007; 13(43): 5765-5770 [PMID: 17963306 DOI: 10.3748/wjg.v13.i43.5765] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
21 Frederiksen C, Qvortrup C, Christensen IJ, Glimelius B, Berglund A, Jensen BV, Nielsen SE, Keldsen N, Nielsen HJ, Brünner N, Pfeiffer P. Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Ann Oncol 2011;22:369-75. [PMID: 20643864 DOI: 10.1093/annonc/mdq354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
22 Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008;2:349-55. [PMID: 19383356 DOI: 10.1016/j.molonc.2008.09.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
23 Elkord E, Hawkins RE, Stern PL. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther. 2008;8:385-395. [PMID: 18352844 DOI: 10.1517/14712598.8.4.385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
24 Patel DK. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008;28:31S-41S. [PMID: 18980550 DOI: 10.1592/phco.28.11-supp.31S] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 El-Mashtoly SF, Yosef HK, Petersen D, Mavarani L, Maghnouj A, Hahn S, Kötting C, Gerwert K. Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. Anal Chem 2015;87:7297-304. [PMID: 26075314 DOI: 10.1021/acs.analchem.5b01431] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
26 Despotovic J, Dragicevic S, Nikolic A. Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p. Cell Biochem Biophys 2021. [PMID: 33826035 DOI: 10.1007/s12013-021-00980-3] [Reference Citation Analysis]
27 Björklund P, Svedlund J, Olsson AK, Akerström G, Westin G. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One. 2009;4:e4243. [PMID: 19158955 DOI: 10.1371/journal.pone.0004243] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
28 Myskowski PL, Halpern AC. Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Curr Allergy Asthma Rep 2008;8:63-8. [PMID: 18377777 DOI: 10.1007/s11882-008-0012-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer 2017;25:2179-85. [DOI: 10.1007/s00520-017-3623-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
30 Matsunaga S, Shuto T, Kawahara N, Suenaga J, Inomori S, Fujino H. Gamma Knife surgery for brain metastases from colorectal cancer. Clinical article. J Neurosurg. 2011;114:782-789. [PMID: 20950083 DOI: 10.3171/2010.9.jns10354] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
31 Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, Rom-Gross E, Bahar S, Omer D, Metsuyanim S, Buzhor E, Jacob-Hirsch J, Goldstein RS, Mark-Danieli M, Dekel B. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 2011;30:1664-80. [PMID: 21472018 DOI: 10.1038/onc.2010.549] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]